1. Home
  2. LPA vs NRXS Comparison

LPA vs NRXS Comparison

Compare LPA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$2.96

Market Cap

93.9M

Sector

N/A

ML Signal

HOLD

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

HOLD

Current Price

$6.68

Market Cap

78.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
NRXS
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
93.9M
78.9M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
LPA
NRXS
Price
$2.96
$6.68
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
274.3K
73.9K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.13
EPS
N/A
N/A
Revenue
N/A
$3,569,282.00
Revenue This Year
N/A
$172.91
Revenue Next Year
N/A
$115.71
P/E Ratio
$11.25
N/A
Revenue Growth
N/A
32.89
52 Week Low
$2.04
$2.20
52 Week High
$6.90
$9.33

Technical Indicators

Market Signals
Indicator
LPA
NRXS
Relative Strength Index (RSI) 40.78 41.66
Support Level $2.59 $6.29
Resistance Level $3.42 $7.71
Average True Range (ATR) 0.28 0.36
MACD -0.07 -0.03
Stochastic Oscillator 10.16 12.00

Price Performance

Historical Comparison
LPA
NRXS

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Share on Social Networks: